Halozyme heads into its third-quarter report with a stock that has already done a lot of celebrating. Shares have climbed nearly 43% since the company's last update, while the S&P 500 went nowhere, and the stock now sits at $128.50, a hair below its post-earnings high of $128.94. That rally followed a quarter in which management raised every major piece of full-year guidance and signed new licensing deals at the fastest clip in company history. The question now is less about whether the business is working and more about how much further it can surprise.

Wall Street expects non-GAAP earnings of $2.28 per share on revenue of about $480.7 million, which would mark roughly 36% revenue growth from the year-ago quarter's $354.3 million and about 40% earnings growth from $1.63. The whisper number of $2.31 sits only slightly above consensus, a modest nudge that signals quiet optimism rather than a dramatically elevated bar. One detail deserves attention: the revenue estimate is essentially flat with the second quarter's $481.0 million. That comparison is less alarming than it looks, because last quarter included $35.5 million in upfront collaboration payments from new deals, which are lumpy and not guaranteed to repeat. Strip those out, and flat headline revenue would still imply healthy growth in the underlying royalty engine.

Royalties are the heart of the story. They reached $308 million last quarter, up 50% from a year earlier and well above the first quarter's $241 million. Management's raised full-year royalty guidance of $1.22 billion to $1.245 billion implies roughly $335 million to $348 million per quarter over the back half of the year. The new CFO was careful to say those second-half step-ups would be smaller than the jump from the first quarter to the second, so a third-quarter royalty figure in the low-to-mid $330 million range would fit the script neatly. A number meaningfully above that would suggest guidance remains conservative; something closer to last quarter's $308 million would raise questions about whether the newer launch products are losing steam.

Those launches are the main drivers to monitor. Ocrevus Zenovo patients grew to 44,000 from 17,500 at the end of last year, Opdivo QVantage is on a path management believes can exceed $1 billion annualized as subcutaneous conversion climbs from around 15% toward a 30% to 40% target, and Rybrevant's subcutaneous version picked up a permanent reimbursement code in July. Continued patient growth and rising conversion rates would validate the thesis that Halozyme's royalty base is broadening rather than relying on a few blockbusters. Progress on the deal front matters too: management expects 13 Enhanze development programs by year-end, up from nine, and any additional activity in the newly opened antibody-drug conjugate and nucleic acid markets would reinforce the idea of a compounding platform.

The guidance picture adds an interesting wrinkle. The full-year consensus of $8.00 in earnings and $1.78 billion in revenue sits below the low end of management's raised ranges of $8.65 to $9.00 and $1.835 billion to $1.91 billion, suggesting some estimates have not fully caught up. That leaves room for upward revisions, but after a raise of this size, simply reaffirming the outlook could feel underwhelming to a market whose sentiment has swung from mildly bearish before the last report to solidly bullish now. The unresolved Merck and Alteogen litigation also remains a binary overhang that a strong quarter cannot fully dispel.

Ultimately, this report hinges on whether royalty growth holds the trajectory management laid out. With the stock testing its highs and trading far above its 200-day average near $82, Halozyme likely needs royalties at or above the implied pace, plus another nudge to guidance, to keep its compounding-engine narrative intact.